地西他滨联合化疗治疗骨髓增生异常综合征转化白血病的临床研究

Clinical research of decitabine combined with chemotherapy in the treatment of myelodysplastic syndrome transformed leukemia

目的探讨地西他滨联合化疗治疗骨髓增生异常综合征转化白血病的疗效。方法将本院2013年1月至2014年1月间骨髓增生异常综合征转化白血病患者68例，随机将其分成研究组与对照组，每组34例。对照组采取常规化疗治疗，研究组采取地西他滨联合化疗，分析比较两组患者的疗效及对患者生存时间的影响。结果研究组治疗总控制率、不良反应率、治疗后的6个月、1年、2年生存及满意度等指标均明显优于对照组患者，两组各项指标之间比较差异有统计学意义（P〈0．05）。结论在骨髓增生异常综合征转化白血病治疗中地西他滨联合化疗方案临床疗效较好，且毒副反应小，患者耐受性好，可提高生存率，建议临床推广应用。

Objective To investigate the efficacy of decitabine combined with chemotherapy in the treatment of myelodysplastic syndrome transformed leukemia. Methods 68 cases of myelodysplastic syndrome transformed leukemia in our hospital from January 2013 to January 2014 were randomly divided into study group and control group, 34 cases in each group. Control group was given conventional chemotherapy treatment, study group was given decitabine combined with chemotherapy. Clinical efficacy and impact on patients＇ survival time of two groups were compared and analyzed. Results The overall control rate of treatment, the rate of adverse reactions, the survival rate 6 months, 1 year, 2 years after treatment, and patients＇ satisfaction of study group were significantly better than those of control group, with statistically significant differences （P〈0.05）. Conclusion The clinical efficacy of decitabine combined with chemotherapy in the treatment of myelodysplastic syndrome transformed leukemia is better, with less toxicity, patients are with well tolerated, survival rate is improved, worthy of clinical application.